Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy - Abstract

Department of Pharmacy, China Medical University, Taichung, Taiwan.

Sex Hormone Research Center, China Medical University Hospital, Taichung, Taiwan.



Androgen-deprivation therapy (ADT) is the most common therapy for advanced prostate cancer, but the prognosis significantly differs among individuals. In this study, we evaluated recently identified 19 prostate cancer susceptibility variants as prognostic predictors for the survival after ADT. A total of 601 prostate cancer patients treated with ADT were enrolled in this study cohort. The prognostic significance of the prostate cancer risk variants on disease progression, prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) after ADT were assessed by Kaplan-Meier analysis and Cox regression model. Two polymorphisms, rs16901979 and rs7931342, were significantly associated with PCSM (P = 0.005 for rs16901979 and P = 0.038 for rs7931342), and rs16901979 was also associated with ACM (P = 0.003) following ADT. Although the effect of rs7931342 was attenuated after controlling for other known clinical prognostic factors, rs16901979 remained a significant predictor for PCSM and ACM after ADT (P= 0.002). Moreover, the addition of the rs16901979 status in current clinical staging system further enhanced the risk prediction on PCSM and ACM particularly for the high-risk patients with distant metastasis (P < 0.017). In conclusion, this is the first study showing that prostate cancer risk variants, such as rs16901979, might improve outcome prediction following ADT, thus allowing identification of high-risk patients who might benefit from appropriate adjuvant therapy.

Written by:
Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, Lan YH, Lu TL, Lee HZ, Chen LM, Ting WC, Hsieh CJ, Huang SP.   Are you the author?

Reference: Int J Cancer. 2011 Mar 28. Epub ahead of print.
doi: 10.1002/ijc.26091

PubMed Abstract
PMID: 21445969 Prostate Cancer Section